AtriCure reports preliminary Q4 revenue $140.5M, consensus $139.29M

Preliminary, unaudited revenue for fourth quarter 2025 is expected to be $140.5M, reflecting growth of approximately 13% over the fourth quarter of 2024. Fourth quarter revenue was driven by continued strong growth in Pain Management, Open Ablation and Open AtriClip devices, the company said. Preliminary, unaudited revenue for full year 2025 is expected to be $534.5M, reflecting growth of approximately 15% over full year 2024. Management now expects full year 2025 positive adjusted EBITDA of approximately $57M-$59M, and full year 2025 adjusted loss per share of approximately (21c)-(18c). FY25 consensus calls for a loss per share of (24c) and revenue of $533.31M.